- Home
- LGI vs INBX Comparison
LGI vs INBX Comparison
Compare LGI & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGI
- INBX
- Stock Information
- Founded
- LGI 2004
- INBX 2010
- Country
- LGI United States
- INBX United States
- Employees
- LGI N/A
- INBX N/A
- Industry
- LGI
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- LGI
- INBX Health Care
- Exchange
- LGI Nasdaq
- INBX Nasdaq
- Market Cap
- LGI 189.3M
- INBX 168.1M
- IPO Year
- LGI N/A
- INBX 2020
- Fundamental
- Price
- LGI $15.52
- INBX $11.18
- Analyst Decision
- LGI
- INBX Hold
- Analyst Count
- LGI 0
- INBX 1
- Target Price
- LGI N/A
- INBX N/A
- AVG Volume (30 Days)
- LGI 41.1K
- INBX 97.5K
- Earning Date
- LGI 01-01-0001
- INBX 05-20-2025
- Dividend Yield
- LGI 7.10%
- INBX 7.56%
- EPS Growth
- LGI N/A
- INBX N/A
- EPS
- LGI N/A
- INBX 112.62
- Revenue
- LGI N/A
- INBX $200,000.00
- Revenue This Year
- LGI N/A
- INBX N/A
- Revenue Next Year
- LGI N/A
- INBX N/A
- P/E Ratio
- LGI N/A
- INBX $0.10
- Revenue Growth
- LGI N/A
- INBX N/A
- 52 Week Low
- LGI $12.66
- INBX $10.80
- 52 Week High
- LGI $16.68
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- LGI 57.99
- INBX 38.27
- Support Level
- LGI $15.34
- INBX $10.90
- Resistance Level
- LGI $15.68
- INBX $12.60
- Average True Range (ATR)
- LGI 0.25
- INBX 0.86
- MACD
- LGI 0.12
- INBX -0.03
- Stochastic Oscillator
- LGI 90.12
- INBX 14.28
About LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.